Literature DB >> 18197002

Clinical aspects of uterine papillary serous carcinoma.

Chad A Hamilton1, Daniel S Kapp, John K Chan.   

Abstract

PURPOSE OF REVIEW: We review the demographic and clinicopathologic characteristics, and prognosis of women diagnosed with uterine papillary serous carcinoma, with a focus on clinical management. RECENT
FINDINGS: Pathologic evaluation of postmenopausal bleeding is preferred for patients who fit the profile of a high-risk endometrial cancer such as uterine papillary serous carcinoma. Women diagnosed with endometrial cancer who fit this profile and all women with uterine papillary serous carcinoma should undergo comprehensive surgical staging and aggressive cytoreduction of extrauterine disease. Adjuvant therapy remains controversial. Several recent investigations reported on the potential benefit of adjuvant chemotherapy, with many recommending additional loco-regional radiation.
SUMMARY: Despite the lack of randomized trials on uterine papillary serous carcinoma, several recent reports have provided insight into the diagnosis, surgical management, and adjuvant treatment of this high-risk endometrial cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18197002     DOI: 10.1097/GCO.0b013e3282f2b10d

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  8 in total

1.  High levels of Nrf2 determine chemoresistance in type II endometrial cancer.

Authors:  Tao Jiang; Ning Chen; Fei Zhao; Xiao-Jun Wang; Beihua Kong; Wenxin Zheng; Donna D Zhang
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma.

Authors:  Mark H Einstein; Marina Frimer; Dennis Y-S Kuo; Laura L Reimers; Keyur Mehta; Subhakar Mutyala; Gloria S Huang; June Y Hou; Gary L Goldberg
Journal:  Gynecol Oncol       Date:  2011-10-27       Impact factor: 5.482

3.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

4.  Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.

Authors:  Christopher J Walker; Mario A Miranda; Matthew J O'Hern; Joseph P McElroy; Kevin R Coombes; Ralf Bundschuh; David E Cohn; David G Mutch; Paul J Goodfellow
Journal:  J Natl Cancer Inst       Date:  2015-09-01       Impact factor: 13.506

Review 5.  Metastatic gynecologic malignancies: advances in treatment and management.

Authors:  John K Chan; Stephanie Chow; Subasish Bhowmik; Amandeep Mann; Daniel S Kapp; Robert L Coleman
Journal:  Clin Exp Metastasis       Date:  2018-06-21       Impact factor: 5.150

6.  DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium.

Authors:  Manohar Pradhan; Ben Davidson; Vera Maria Abeler; Håvard Emil Danielsen; Claes Göran Tropé; Gunnar Balle Kristensen; Björn Åke Risberg
Journal:  Virchows Arch       Date:  2012-07-24       Impact factor: 4.064

7.  Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases.

Authors:  Yao Wang; Mei Yu; Jia-Xin Yang; Dong-Yan Cao; Keng Shen; Jing-He Lang
Journal:  Cancer Manag Res       Date:  2018-10-25       Impact factor: 3.989

8.  In search for biomarkers and potential drug targets for uterine serous endometrial cancer.

Authors:  Giorgia Dinoi; Andrea Mariani; Enrica Martinelli; Alessandra Ciucci; Gian Franco Zannoni; Amy L Weaver; Gary L Keeney; George Vasmatzis; Panos Z Anastasiadis; Francesco Fanfani; Giovanni Scambia; Daniela Gallo
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-23       Impact factor: 4.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.